Predictive Value of MRI for Clinical Outcomes

Summary of presentations from the Genzyme-supported satellite symposium, held at the 22nd Annual Meeting of the European Charcot Foundation, Baveno, Italy, on 20th-22nd November 2014

Chairperson: Massimo Filippi1
Speakers: Maria Pia Sormani,2 Andrew Chan,3 Hans-Peter Hartung4

1. Vita-Salute San Raffaele University, Milan, Italy
2. University of Genoa, Genoa, Italy
3. Ruhr University Bochum, Bochum, Germany
4. University of Düsseldorf, Düsseldorf, Germany

Disclosure: Professor Massimo Filippi serves on the scientific advisory boards for Teva and Biogen Idec; has received compensation for consulting services and/or speaking activities from Bayer Schering Pharma, Biogen Idec, Merck Serono, Sanofi-Aventis, and Teva Pharmaceutical Industries; and has received research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer’s Drug Discovery Foundation (ADDF), and the Jacques and Gloria Gossweiler Foundation (Switzerland). Professor Maria Pia Sormani has received honoraria and speakers’ fees from Novartis, Biogen Idec, Genzyme (a  Sanofi company), Roche, and Merck Serono. Professor Andrew Chan has received speakers’ honoraria,  contributed to advisory boards, or received research support from Almirall, Biogen Idec, Bayer Schering, Genzyme, Merck Serono, Novartis Pharma, Teva Pharmaceutical Industries, and Sanofi. Professor HansPeter Hartung declares the receipt of honoraria and consultation fees from Biogen Idec GmbH, GeNeuro, Opexa Therapeutics, Merck Serono, Teva, Genzyme (a Sanofi company), MedImmune, Hoffmann-LaRoche, Novartis, and Bayer.
Acknowledgements: Writing assistance was provided by Dr Nicola Ray, apothecom scopemedical Ltd.
Support: The publication of this article was funded by Genzyme. The views and opinions expressed are those of the authors.
Citation: EMJ Neurol. 2015;3(Suppl 2):2–7.

Meeting Summary

The meeting outlined the evidence that the use of magnetic resonance imaging (MRI) markers as  surrogate endpoints in clinical trials of relapsing-remitting multiple sclerosis (MS) is both valid and  informative. The mechanisms of action of teriflunomide (Aubagio®) and alemtuzumab (Lemtrada®), both treatments for relapsing-remitting MS, were discussed, and their Phase II and III safety and efficacy data were reviewed alongside the MRI-derived outcome measures.

Download (PDF, 98KB)

Comments are closed.